No Data
No Data
What investment opportunities are available in Hong Kong and the United States stock markets as the Federal Reserve is about to cut interest rates?
This week, the reason for the Fed's interest rate cut has been further strengthened. Recently, a cluster of U.S. macroeconomic data has weakened. After the release of weak data last week such as unemployment rate, PMI, and durable goods orders, June CPI also weakened this week, boosting market expectations for Fed interest rate cuts. After the Fed started the interest rate cut cycle, real estate stocks, pharmaceutical stocks, and other interest rate-related sectors are expected to be favored by the market. Multiple data shows that the US economy is cooling down and US June CPI has fallen for the third consecutive month, indicating that the most severe inflation in 40 years in the US is steadily subsiding. Thursday's data shows that the US overall in June
Hong Kong stocks rebounded again, with pharmaceutical stocks rising, and the industry's investment and financing are expected to hit bottom and rebound. The release of innovative drug policies has provided bullish signals.
According to the Zhongtong Finance APP, pharmaceutical stocks have risen again. As of press time, Kexing Biotech-B (06990) rose 9.07%, reporting HKD 155.1; Zai Lab (09688) rose 4.63%, reporting HKD 14.02; Genscript Biotech (01548) rose 4.59%, reporting HKD 10.02; and Innocare (09969) rose 4.57%, reporting HKD 5.03. On the news front, the US June CPI slowed down more than expected, pushing the probability of a rate cut in September to nearly 90%. Pacific Securities pointed out that as the Fed's rate hike cycle comes to an end in the future, liquidity is expected to gradually ease.
Innocare (09969) granted 2.79 million restricted stock units.
Innocare (09969) announced on June 28, 2024 that the company had implemented a stock-based incentive plan for 2023.
Hong Kong stocks surged | Innocare (09969) rose more than 4%, and the company's tumor products are steadily expanding their indications. Recently announced the highest to receive 3 billion yuan of financial management.
Innocare (09969) rose more than 4%. As of the time of publication, it has risen 4.3%, with a price of HKD 4.85 and a turnover of HKD 8.87 million.
Innocare (09969) plans to use up to 3 billion yuan of idle self-owned funds for money market management.
Innocare (09969) announced its intention to use its own unused capital of not more than RMB 3 billion to purchase ...
Innocare (09969): The first vesting condition of the 2023 Star Market restricted stock incentive plan has been achieved, and about 1.6348 million shares are expected to vest.
Innocare (09969) announced that according to the Measures for the Administration of Stock-based Incentives of Listed Companies and the Science and Technology Innovation Board in 2023...
No Data